NCT06107608Recruiting
Molecular Imaging of FAP Expressing Cancer-associated Fibroblasts in NSCLC Treated With Immune-checkpoint Inhibitors
Source: ClinicalTrials.gov · Last updated 31 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Evaluation of the relation between baseline fibroblast activation protein (FAP) expression based on Ga-FAPI uptake with patient outcome among NSCLC patients receiving immunotherapy for recurrent/metastatic disease.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 58 (estimated)
- First submitted
- 26 Sept 2023
- Start date
- 13 Jun 2023
- Primary completion date
- 1 Jul 2027
- Lead sponsor
- Jules Bordet Institute
- Diseases
- Lung cancer
- NCT number
- NCT06107608
What you commit to
- Study type: Interventional
- Planned participants: 58
- From 13 Jun 2023 to the primary completion date, 1 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous or concurrent malignancy diagnosed within the last 2 years except adequately treated in situ carcinoma of the cervix uteri, localised (T1N0) low grade (Gleason score 6) prostate cancer undergoing active surveillance and basal or squamous cell skin cancer.
Other illness
- Surgery and/or radiotherapy to thoracic region within the last 8 weeks or anti-cancer systemic therapy within the last 2 weeks.
- Subjects with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study.
Lab values
- Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) and c-ros oncogene (ROS1) mutations.
Other
- Pregnant and lactating women
Who the study is looking for
- Age above 18 years.
- Pathologically- proven non-small-cell lung cancer (NSCLC).
- Proposed for treatment with anti-PD-(L)1 alone or in combination with chemotherapy and/or anti-CTLA4 in the advanced setting.
- ECOG Performance status ≤2.
- Patient's written informed consent obtained prior to any study procedure.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Jules Bordet Coordinator of this site? Confirm its status | Brussels | Belgium | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.